Preliminary Structure–Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains
- 3 May 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (10) , 4093-4103
Abstract
Tuberculosis (TB) remains one of the leading causes of mortality and morbidity worldwide, with approximately one-third of the world’s population infected with latent TB. This is further aggravated by HIV coinfection and the emergence of multidrug- and extensively drug-resistant (MDR and XDR, respectively) TB; hence the quest for highly effective antitubercular drugs with novel modes of action is imperative. We report herein the discovery of an indole-2-carboxamide analogue, 3, as a highly potent antitubercular agent, and the subsequent chemical modifications aimed at establishing a preliminary body of structure–activity relationships (SARs). These efforts led to the identification of three molecules (12–14) possessing an exceptional activity in the low nanomolar range against actively replicating Mycobacterium tuberculosis, with minimum inhibitory concentration (MIC) values lower than those of the most prominent antitubercular agents currently in use. These compounds were also devoid of apparent toxicity to Vero cells. Importantly, compound 12 was found to be active against the tested XDR-TB strains and orally active in the serum inhibition titration assay.Keywords
This publication has 25 references indexed in Scilit:
- The challenge of new drug discovery for tuberculosisNature, 2011
- Global tuberculosis drug development pipeline: the need and the realityThe Lancet, 2010
- Epidemiology and Challenges to the Elimination of Global TuberculosisClinical Infectious Diseases, 2010
- Linezolid in the Treatment of Multidrug‐Resistant TuberculosisClinical Infectious Diseases, 2010
- Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine ModelPLOS Medicine, 2007
- HTS, Chemical Hybridization, and Drug Design Identify a Chemically Unique Antituberculosis Agent–Coupling Serendipity and Rational Approaches to Drug DiscoveryChemMedChem, 2007
- Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis : Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo EfficacyAntimicrobial Agents and Chemotherapy, 2007
- Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo ModelsAntimicrobial Agents and Chemotherapy, 2005
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005
- Directly observed therapy (DOT) for tuberculosis: why, when, how and if?Thorax, 1999